P/B
412,6
Tiziana Life Sciences
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
$21.5M
Market Cap • 9/14/2026
1998
(28 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United Kingdom
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
21,5M
EV
17,9M
EV/Revenue
0
EV/EBITDA
-0,9
EV/EBIT
-0,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-47,6%
Total Yield
-47,6%
Payout
0%
Retained Earnings
-163,1M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
9%
Capex/OCF
-0,2%
SBC/OCF
—
% PPE
4,3%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
-5,5%
CAGR Net Income 5Y
-8,2%
CAGR EPS 5Y
-9,9%
CAGR OCF 5Y
2,5%
Leverage
N.D./EBITDA
0,2
Debt/Equity
0%
Current Ratio
0,8
Quick Ratio
0,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!